Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial

Update your browser to view ScienceDirect correctly.

Your technical details and browser version:

Request ID: 8f03faa23fb42314-LAX IP: 116.62.10.13 UTC time: 2024-12-11T08:07:05+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4